Filing Analysis
Achieve Life Sciences, Inc. has entered into an At-The-Market (ATM) offering agreement with Jefferies LLC to sell up to $150 million in common stock. The proceeds are intended for the commercialization and Phase 3 clinical trials of cytisinicline, as well as general working capital.
🚩 Red Flags
- Potential significant dilution for existing shareholders due to the $150 million ATM program.
- The need for large-scale funding suggests high cash burn associated with upcoming Phase 3 trials.
📋 Key Facts
- Entered into an Open Market Sale Agreement (ATM Program) with Jefferies LLC on August 14, 2026.
- Maximum aggregate offering price is $150.0 million.
- Jefferies will receive compensation of up to 3.0% of the aggregate gross proceeds.
- Proceeds are earmarked for cytisinicline commercialization, Phase 3 clinical trials for e-cigarette cessation, and working capital.
Achieve Life Sciences, Inc. filed an 8-K to announce its financial results for the second quarter ended June 30, 2026.
📋 Key Facts
- Report date: August 11, 2026
- Reporting period: Second Quarter ended June 30, 2026
- The filing includes a press release regarding financial results (Exhibit 99.1)
- Signed by Mark Oki, Chief Financial Officer
Achieve Life Sciences, Inc. reported the results of its Annual Meeting of Stockholders held on July 2, 2026. The meeting resulted in the election of nine directors and the approval of a significant increase in authorized common stock.
🚩 Red Flags
- Significant increase in authorized share count (doubled from 150M to 300M), which can lead to future dilution if used for equity financing.
📋 Key Facts
- Annual Meeting held on July 2, 2026.
- Nine directors were elected to serve until the next annual meeting: Jeffrey Farrow, Andrew D. Goldberg, Lucian Iancovici, Chris Martin, Nancy R. Phelan, Aaron Royston, Thomas Sellig, Richard Stewart, and Reid Waldman.
- Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending Dec 31, 2026.
- Non-binding advisory vote (Say-on-Pay) approved executive compensation.
- Shareholders approved a Certificate of Amendment to increase authorized common stock from 150,000,000 to 300,000,000 shares.
Achieve Life Sciences appointed Jeff Farrow and Reid Waldman, M.D. to its Board of Directors on May 29, 2026. Both directors were assigned to specific committee roles, including Audit and Compensation chairs.
📋 Key Facts
- Appointment of Jeff Farrow and Reid Waldman, M.D. as directors effective May 29, 2026.
- Jeff Farrow appointed as Chair of the Audit Committee and member of the Nominating and Governance Committee.
- Dr. Reid Waldman appointed as Chair of the Compensation Committee and member of the Commercial Committee.
- Directors receive a pro-rated $40,000 annual retainer for fiscal year 2026 plus additional committee cash compensation.
- Each new director granted stock options to purchase 47,250 shares of common stock, vesting monthly over three years.
Achieve Life Sciences announced a significant leadership transition, including the resignation of its Board Chairman and Chief Commercial Officer, alongside the appointment of a new director designated by Frazier Life Sciences.
🚩 Red Flags
- Simultaneous departure of the Board Chairman and a C-suite executive (CCO).
- Multiple 8-K items (2.02 and 5.02) filed in a single report.
📋 Key Facts
- Chairman Thomas King is resigning effective June 8, 2026, with Lucian Iancovici, MD, appointed as the new Chair.
- Chief Commercial Officer Jaime Xinos will depart the company effective May 31, 2026.
- Christopher Martin was appointed to the Board effective May 11, 2026, pursuant to a designation right held by Frazier Life Sciences.
- Mr. Martin will receive a pro-rated $40,000 annual retainer and a stock option for 47,250 shares vesting over three years.
- The company also furnished its Q1 2026 financial results ending March 31, 2026.
Achieve Life Sciences announced a massive $180 million private placement of common stock and warrants alongside a leadership transition, with CEO Richard Stewart stepping down and Andrew Goldberg being appointed as the new CEO.
🚩 Red Flags
- Extremely high dilution potential from the issuance of nearly 100 million shares and warrant shares.
- Coincidental departure of the sitting CEO at the time of a major capital raise and institutional entry.
📋 Key Facts
- Entered into a Securities Purchase Agreement for the sale of 49,418,069 shares and 100,500 pre-funded warrants at $3.635 per unit.
- Issued accompanying warrants for 49,518,569 shares at an exercise price of $3.51, which could provide an additional $173.8 million in gross proceeds.
- Anticipated gross proceeds of $180.0 million to fund Phase 3 clinical trials for cytisinicline and commercialization efforts.
- CEO Richard Stewart to step down effective April 18, 2026, remaining on the Board; Andrew Goldberg appointed as CEO and President.
- New CEO Andrew Goldberg's compensation includes a $665,000 base salary and equity awards totaling approximately 9.5% of fully diluted capitalization, including performance-based units tied to 2x-9x share price milestones.
Achieve Life Sciences, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The disclosure was made via a press release on March 24, 2026, and furnished under Item 2.02.
📋 Key Facts
- The company reported financial results for the period ending December 31, 2025.
- The report was filed on March 24, 2026.
- The financial information was furnished as Exhibit 99.1.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits).
Achieve Life Sciences, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2025. The filing serves as a formal notice that a press release containing these results was issued on November 6, 2025.
📋 Key Facts
- Reporting period: Third Quarter ended September 30, 2025.
- Filing date: November 6, 2025.
- The company furnished a press release (Exhibit 99.1) regarding its financial condition and results of operations.
Achieve Life Sciences, Inc. announced the resignation of Dr. Cindy Jacobs from her roles as Chief Medical Officer and President, effective October 6, 2025. The company has entered into a separation agreement that includes a consulting arrangement tied to the FDA approval of cytisinicline.
🚩 Red Flags
- Departure of a key executive (CMO and President) during a critical regulatory phase (NDA pending).
- Contingent compensation/consultancy tied directly to FDA approval creates potential alignment or incentive-based scrutiny.
📋 Key Facts
- Dr. Cindy Jacobs resigned as CMO and President on October 6, 2025.
- A Separation Agreement was executed effective October 6, 2025.
- Dr. Jacobs will serve as a consultant until the first business day following FDA approval of the cytisinicline New Drug Application (NDA).
- Severance includes a $101,296 lump-sum cash payment (prorated 2025 bonus).
- Accelerated vesting of time-based options from Jan 2023 and Jan 2024 occurs upon termination of consultancy following NDA approval.
- The company will reimburse up to $10,000 in legal fees for the agreement negotiation.
Dr. Cindy Jacobs has resigned from her dual role as Chief Medical Officer and President, effective October 6, 2025. The company is currently negotiating a consulting agreement to retain her in an advisory capacity.
🚩 Red Flags
- Departure of a dual-role executive (CMO and President) can signal internal instability or strategic shifts in leadership.
- Loss of key medical leadership in a life sciences company may impact clinical development continuity.
📋 Key Facts
- Resignation date: September 5, 2025
- Effective date of departure: October 6, 2025
- Departing officer: Dr. Cindy Jacobs (Chief Medical Officer and President)
- The company is negotiating a consulting agreement for continued advisory services.
Achieve Life Sciences, Inc. filed an 8-K to furnish its second quarter financial results for the period ended June 30, 2025.
📋 Key Facts
- The filing relates to the announcement of Q2 2025 financial results.
- Results were announced via press release on August 7, 2025.
- The report was signed by CFO Mark Oki.
Achieve Life Sciences announced a significant public offering of 15 million common shares and 15 million accompanying warrants at $3.00 per unit. The company expects to net approximately $41.3 million from the transaction, which is expected to close on June 30, 2025.
🚩 Red Flags
- Significant dilution potential due to the issuance of 15 million new shares and 15 million warrants.
- Warrant overhang: The accompanying warrants allow for further dilution upon exercise.
📋 Key Facts
- Offering size: 15,000,000 shares of common stock and 15,000,000 accompanying warrants.
- Underwriters include Citizens JMP Securities, LLC and Raymond James & Associates, Inc.
- Public offering price: $3.00 per share and warrant unit.
- Warrants are exercisable at $3.00 or via pre-funded warrants at $2.999.
- Underwriters have a 30-day option to purchase an additional 2,250,000 shares/warrants.
- Estimated net proceeds: Approximately $41.3 million (assuming no overage exercise).
- Expected closing date: June 30, 2025.
Achieve Life Sciences, Inc. held its Annual Meeting of Stockholders on June 4, 2025. Shareholders successfully elected seven directors and ratified the appointment of PricewaterhouseCoopers LLP as independent auditors, but failed to approve an amendment to increase shares in the 2023 Non-Employee Director Equity Incentive Plan.
🚩 Red Flags
- Shareholders rejected the amendment to increase shares for the Non-Employee Director Equity Incentive Plan, indicating potential dissatisfaction with dilution or compensation structures.
- High number of non-votes/broker non-votes (over 11 million) suggests significant shareholder abstention or lack of engagement.
📋 Key Facts
- Annual Meeting held on June 4, 2025.
- Seven directors (Stuart Duty, Bridget Martell, Thomas B. King, Thomas Sellig, Richard Stewart, Nancy R. Phelan, and Kristen Slaoui) were elected to serve until the next annual meeting.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2025.
- The proposal to amend the 2023 Non-Employee Director Equity Incentive Plan to increase available shares was NOT approved (6,736,105 'For' vs 7,982,633 'Against').
- A significant number of non-votes/broker non-votes (11,422,484) were recorded across all voting items.
Achieve Life Sciences, Inc. filed an 8-K to furnish its quarterly earnings press release for the first quarter ended March 31, 2025.
📋 Key Facts
- The filing is a standard announcement of Q1 2025 financial results (ended March 31, 2025).
- The report was filed on May 13, 2025.
- Financial results were released via press release attached as Exhibit 99.1.
Achieve Life Sciences, Inc. filed an 8-K to announce its financial results for the fourth quarter and full fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: March 11, 2025
- Reporting period: Q4 and Full Year ended December 31, 2024
- The filing includes a press release (Exhibit 99.1) containing the financial results.
- Signed by Mark Oki, Chief Financial Officer.
Achieve Life Sciences announced that its Data Safety Monitoring Committee (DSMC) completed a second independent review of the ORCA-OL clinical trial. The committee found no unexpected adverse events and confirmed that the study can proceed as planned.
📋 Key Facts
- The DSMC conducted its second independent review of the ongoing ORCA-OL trial.
- The trial evaluates long-term exposure to a 3 mg cytisinicline treatment regimen for smokers/vapers.
- No unexpected treatment-related adverse events were identified during the review.
- Participant adherence to medication was reported as 'excellent'.
- The DSMC concluded the study may continue without modifications.
Achieve Life Sciences, Inc. announced a change in its Board of Directors effective January 6, 2025. Dr. Vaughn Himes resigned from the Board but will continue as a consultant, and two new directors, Nancy R. Phelan and Kristen B. Slaoui, Ph.D., were appointed.
🚩 Red Flags
- None identified; the departure of a director is mitigated by the fact that they are continuing as a consultant and explicitly stated there were no disagreements.
📋 Key Facts
- Dr. Vaughn Himes resigned from the Board effective January 6, 2025; he remains with the company as a consultant.
- Nancy R. Phelan was appointed to the Board effective January 6, 2025.
- Kristen B. Slaoui, Ph.D., was appointed to the Board effective January 6, 2025.
- Incoming directors will receive an annual retainer of $40,000 for fiscal year 2025.
- Each new director is granted stock options for 47,250 shares, vesting monthly over three years (effective Jan 13, 2025).
- The company stated Dr. Himes' resignation was not due to any disagreement regarding operations, policies, or practices.
Achieve Life Sciences, Inc. announced the appointment of Mark K. Oki as Chief Financial Officer and principal financial officer, effective December 5, 2024.
📋 Key Facts
- Mark K. Oki appointed CFO/Principal Financial Officer effective Dec 5, 2024.
- Oki previously served as CFO of Aytu Biopharma, Inc. and Vivus LLC.
- Annual base salary set at $450,000.
- Discretionary bonus potential up to 40% of base salary.
- Equity compensation includes an option for up to 72,000 shares and 168,000 performance-based RSUs.
- Severance terms include 12 months' salary (or 24 months in a change in control scenario) plus healthcare coverage.
Achieve Life Sciences, Inc. filed an 8-K to announce its financial results for the third quarter ended September 30, 2024.
📋 Key Facts
- The filing is a routine announcement of Q3 2024 financial results.
- Results were announced via press release on November 7, 2024.
- Exhibit 99.1 contains the full press release detailing the quarterly performance.
Achieve Life Sciences, Inc. entered into an At-The-Market (ATM) offering agreement with Jefferies LLC to sell up to $50,000,000 in common stock. The proceeds are intended to fund clinical development of cytisinicline and general working capital.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $50M ATM program.
- The scale of the offering ($50M) relative to typical micro-cap market caps suggests a high dependency on equity financing for operations.
📋 Key Facts
- Entered into an Open Market Sale Agreement (ATM Program) on September 27, 2024.
- Maximum aggregate offering price: $50,000,000.
- Sales agent: Jefferies LLC.
- Jefferies to receive compensation of up to 3.0% of gross proceeds.
- Shares will be issued under a previously filed Form S-3 Registration Statement (dated June 28, 2024).
- Proceeds earmarked for cytisinicline clinical development and general corporate purposes.
Achieve Life Sciences announced a major leadership transition effective August 21, 2024. CEO John Bencich resigned from his roles as CEO, CFO, and Director, while Richard Stewart returns to the CEO role, triggering several committee reassignments.
🚩 Red Flags
- Sudden departure of both CEO and CFO (Principal Financial Officer) simultaneously.
- Significant cash severance obligations for the departing CEO (18 months of salary + benefits).
- Leadership instability indicated by the rapid reshuffling of Board committees.
📋 Key Facts
- John Bencich resigned as CEO, Principal Executive Officer, and Principal Financial Officer effective August 21, 2024.
- Bencich will serve as an advisor until December 31, 2024.
- Richard Stewart appointed as new CEO, Principal Executive Officer, and Principal Financial Officer effective August 21, 2024.
- Thomas B. King appointed as Executive Chairman; he also stepped down from the Audit, Compensation, and Nominating committees.
- Bencich's separation includes a lump-sum cash severance of 18 months of base salary and 18 months of healthcare coverage.
Achieve Life Sciences, Inc. filed an 8-K to furnish its quarterly earnings press release for the second quarter ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of Q2 2024 financial results.
- Report date: August 13, 2024.
- Financial results for the period ending June 30, 2024, are provided in Exhibit 99.1.
Achieve Life Sciences entered into a $10.0 million contingent convertible debt agreement with Silicon Valley Bank (a division of First-Citizens Bank & Trust Company) to refinance existing debt. The agreement includes potential for an additional $10.0 million in tranches tied to FDA milestones and contains significant conversion features that could lead to equity dilution.
🚩 Red Flags
- Significant potential dilution via convertible debt features at prices ($7.00 and ~$4.85+) that may be below current market value.
- Debt is secured by substantially all company assets (excluding IP).
- Automatic conversion triggers linked to high stock price targets could create significant downward pressure on share price upon conversion.
- Refinancing of previous debt indicates ongoing need for external liquidity.
📋 Key Facts
- Entered into a contingent convertible debt agreement on July 25, 2024.
- Initial term loan amount: $10.0 million (first tranche advanced July 25, 2024).
- Potential additional tranches: $5.0 million if FDA accepts New Drug Application for cytisinicline by Oct 31, 2025; another $5.0 million at Lender's discretion by Dec 31, 2025.
- Maturity date is December 1, 2027 (extendable to June 1, 2028).
- Interest rate: Floating rate of the greater of 7.0% or Prime minus 1.0%.
- Initial conversion price for first tranche: $7.00 per share.
- Subsequent conversion price: Greater of $4.854 or 150% of a specific market-based formula.
- Automatic conversion trigger if stock price exceeds $24.00 (for first tranche) or 3x Subsequent Conversion Price for later tranches, subject to liquidity conditions.
Achieve Life Sciences entered into a non-binding term sheet to refinance up to $20 million in outstanding term loans with Silicon Valley Bank. The proposed terms include an extension of maturity to June 1, 2028, and interest-only payments through at least December 31, 2025.
🚩 Red Flags
- Imminent debt maturity (August 1, 2024) creates significant liquidity pressure if refinancing fails.
- Non-binding nature of the term sheet means the company's solvency remains uncertain in the short term.
- The need to refinance existing debt suggests potential cash flow constraints.
📋 Key Facts
- Entered into a non-binding term sheet in June 2024 with Silicon Valley Bank (SVB) and affiliates.
- Proposed facility amount: up to $20 million.
- New maturity date: June 1, 2028.
- Interest-only payments scheduled through at least December 31, 2025.
- Current loan maturity date is August 1, 2024.
- The agreement is non-binding and there is no guarantee a definitive agreement will be reached.
Achieve Life Sciences, Inc. held its Annual Meeting of Stockholders on June 5, 2024. The meeting resulted in the election of eight directors and the ratification of PricewaterhouseCoopers LLP as the company's independent auditor for the fiscal year ending December 31, 2024.
📋 Key Facts
- Annual Meeting held on June 5, 2024.
- Eight directors were elected to serve until the next annual meeting: John Bencich, Stuart Duty, Vaughn Himes, Cindy Jacobs, Thomas B. King, Bridget Martell, Thomas Sellig, and Richard Stewart.
- PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024 with 24,825,016 votes in favor.
Achieve Life Sciences, Inc. filed an 8-K to furnish its quarterly press release announcing financial results for the first quarter ended March 31, 2024.
📋 Key Facts
- The filing is a routine announcement of Q1 2024 financial results.
- The report date is May 9, 2024.
- Financial results were released via press release (Exhibit 99.1).
Achieve Life Sciences, Inc. filed an 8-K to furnish its press release announcing financial results for the fourth quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Reported date: March 28, 2024
- Reporting period: Fourth quarter and full year ended December 31, 2023
- The filing is a standard earnings release announcement (Item 2.02)
Achieve Life Sciences, Inc. entered into a securities purchase agreement to conduct a registered offering of up to 13,086,151 shares at $4.585 per share and a concurrent private placement of warrants. The net proceeds are intended to fund the clinical development of cytisinicline through its expected NDA submission in the first half of 2025.
🚩 Red Flags
- Significant dilution potential from the issuance of over 13 million shares and subsequent warrant exercises.
- Warrants are tied to a specific regulatory milestone (FDA NDA acceptance), creating binary outcome risk for investors.
📋 Key Facts
- Registered offering of up to 13,086,151 shares at $4.585 per share.
- Concurrent private placement of warrants with an exercise price of $4.906 per share (or $4.905 for pre-funded warrants).
- Estimated net proceeds from the offering: approximately $56.2 million.
- Potential additional gross proceeds of $64.2 million if all warrants are exercised in full.
- Warrants are exercisable until 30 days after public disclosure of FDA acceptance of an NDA for cytisinicline (Day 74 Letter).
- Use of proceeds: clinical development of cytisinicline, ORCA-OL trial, and working capital.
- Termination of existing At-the-Market (ATM) Sales Agreement with Virtu Americas LLC as of February 28, 2024.